Viral hepatitis is the inflammation of
the liver caused by a virus. Five different types of hepatitis virus
exist, namely: A, B, C, D and E. All types cause short term, or acute
infection. Only hepatitis B, C and D viruses cause long-term infection,
called chronic hepatitis which could lead to life-threatening
complications such as cirrhosis (liver scarring), liver failure, and
liver cancer. Viral hepatitis is the leading cause of liver cancer and
most common reason for liver transplantation. Liver cancer is one of the
ten most common cancers worldwide. In Nigeria, it has been reported
that over 11,000 persons die yearly of liver cancer. Hepatitis B and C
viruses have the highest prevalence of infection, while over 240 million
people worldwide are chronically infected with hepatitis B virus (HBV);
about 150 million are infected with hepatitis C virus. More than
780,000 people die every year due to the consequences of hepatitis B. It
is an important occupational hazard for health workers. The World
Health Organisation has recognised the HBV as a silent killer. The
infection is preventable with the currently available safe and effective
vaccine.
Continue reading after the cut.....
Continue reading after the cut.....
Hepatitis B virus is transmitted through
contact with the blood or other body fluids of an infected person. The
routes of transmission include the following: Transfusion of unscreened
blood and blood products, unsterilised medical or dental equipment,
mother to child transmission during childbirth, and sharing equipment
for injecting drugs. Other methods include sharing razors, toothbrushes
or other household articles; tattooing and body piercing using
unsterilised equipment; unprotected sex with an infected person.
In acute stage, most people do not
experience any symptom but for those who manifest, the symptoms include:
Yellowing of the skin and eyes (jaundice), dark urine, extreme fatigue,
nausea, vomiting and abdominal pain. In chronic cases, liver infection
can later develop into cirrhosis of the liver or liver cancer. Over 90
per cent of healthy adults infected, recover and completely rid of the
virus within six months. Children who are infected when less than six
years of age are at risk of acquiring chronic infection while less than
five per cent of adults acquiring the infection will develop the chronic
stage of the disease. Most people in sub-Saharan Africa become infected
during childhood and five to 10 per cent of the adult population is
chronically infected.
There is no specific treatment for acute
infection except proper nutrition and fluid replacement. For chronic
infection, oral antiviral agents are used. Treatment does not cure but
slows the progression of cirrhosis, reduces incidence of cancer and
improves long term survival. Treatment, however, is not readily
accessible in many resource-constrained settings. However, measures to
prevent of hepatitis B infection include the following:
- Health education for the public and health workers
- Immunisation of non-immune persons
- Screening and vaccination of health workers
- Screening of pregnant women and immunisation of babies born to infected women
- Blood and organ screening before transfusion or transplantation
- Proper disposal of sharps and no recycling of disposable instruments used for medical procedures
- Sterilisation of instruments used by traditional medical practitioners
- Access to post-exposure prophylaxis
- Practise Abstinence, Be faithful and Condom use
Similarly, hepatitis C virus is a blood
borne virus and the most common modes of infection are through unsafe
injection practices; inadequate sterilisation of medical equipment in
some health care settings; transfusion of unscreened blood and blood
products. About 130-150 million people globally have chronic hepatitis C
infection. A significant number of those who are chronically infected
will develop liver cirrhosis or liver cancer. Between 350,000 and
500,000 people die each year from hepatitis C-related liver diseases.
Antiviral medicines can cure hepatitis C infection but access to
diagnosis and treatment is low. Treatment is successful in 50 to 90 per
cent of persons but some infected persons spontaneously clear the virus
within six months from their system. Others develop chronic HCV
infection and the risk of cirrhosis of the liver is 15 and 30 per cent
within 20 years. Currently, there is no vaccine for hepatitis C;
however, research in this area is ongoing.
It is very important to know your
hepatitis B and C status in order to reduce the risk of infecting others
if you are infected, consider your treatment options and
self-management strategies as early as possible. Knowing your status
will also help to prevent complications such as liver cirrhosis and
cancer and improve the quality of life. In Nigeria, it has been found
that people report for health care only when the viral disease has
advanced and the risk of developing cirrhosis and liver cancer is very
high. For that reason, the Nigerian Institute of Medical Research, Lagos
will mark the 2015 World Hepatitis Day by having a road walk to
sensitise the public, organise a symposium in the Institute for more
awareness creation and also provide free screening and vaccination on
July 28 in her premises in Yaba. So, we urge you to prevent hepatitis
and act now.
- DR Rosemary Audu/ Punch
Share your thoughts....thanks!
ReplyDeleteThank you for sharing such wonderful information!In my opinion, Keep a healthy life by consuming healthy food and doing exercise regularly is the best healthy formula.
regards,
Medical Jobs Australia